|
C5ORF33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.88178419700125E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62614366416847E-12 |
| Normal-vs-Stage2 |
2.44719799979976E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
2.449800E-02 |
| Stage1-vs-Stage3 |
5.696000E-02 |
| Stage1-vs-Stage4 |
4.301800E-03 |
| Stage2-vs-Stage3 |
3.559800E-03 |
| Stage2-vs-Stage4 |
2.387900E-04 |
| Stage3-vs-Stage4 |
2.718200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.55111512312578E-16 |
| Normal-vs-AfricanAmerican |
1.1754042184009E-11 |
| Normal-vs-Asian |
1.62492241884138E-12 |
| Caucasian-vs-AfricanAmerican |
8.689000E-01 |
| Caucasian-vs-Asian |
6.507400E-01 |
| AfricanAmerican-vs-Asian |
6.386800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.4432899320127E-15 |
| Male-vs-Female |
1.474020E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(81-100Yrs) |
8.0379999999991E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.470000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.320800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.154800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.733600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.830000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.177400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.53059999999472E-06 |
| Classical-VS-Follicular |
9.552500E-04 |
| Classical-VS-Other |
3.365200E-01 |
| Classical-VS-Normal |
6.43929354282591E-15 |
| Tall-VS-Follicular |
1.12429998644359E-09 |
| Tall-VS-Other |
2.211600E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.190200E-02 |
| Follicular-VS-Normal |
1.27829968832316E-11 |
| Other-VS-Normal |
3.50869999721226E-10 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.44249065417534E-15 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
4.413900E-02 |
|
|
